Palivizumab
Synagis
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
NADAC/unit
N/A
No Shortage
Active Shortages
2025-08-13 Discontinuation of the manufacture of the drug. Product expected to be available through September 2026., Swedish Orphan Biovitrum AB
2025-08-13 Discontinuation of the manufacture of the drug. Product expected to be available through July 2026., Swedish Orphan Biovitrum AB
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.